- Home
- PRTA vs SHOE Comparison
PRTA vs SHOE Comparison
Compare PRTA & SHOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTA | SHOE |
|---|---|---|
| Founded | 2012 | 1978 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 368.3M |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PRTA | SHOE |
|---|---|---|
| Price | $8.76 | $14.24 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.40 | N/A |
| AVG Volume (30 Days) | 508.2K | ★ 737.4K |
| Earning Date | 11-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | ★ 4.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | 0.02 |
| Revenue | $814,000.00 | ★ $1,135,324,000.00 |
| Revenue This Year | $754.03 | N/A |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | ★ $32.27 | $703.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $10.18 |
| 52 Week High | $11.80 | $16.29 |
Technical Indicators
Market Signals| Indicator | PRTA | SHOE |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 60.44 |
| Support Level | $8.08 | $14.00 |
| Resistance Level | $9.18 | $16.00 |
| Average True Range (ATR) | 0.38 | 0.53 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 58.18 | 96.96 |
Price Performance
Historical ComparisonAbout PRTA Prothena Corporation plc
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
About SHOE Shoe Station Group Inc. Common Stock
Shoe Station Group Inc is a one-stop family footwear destination that offers an impressive selection from top brands. It is a fashion destination for footwear, southern-inspired accessories, and apparel. The group has physical stores throughout five Southern states and is available online at ShoeStation.com, shipping all across the U.S. Its offer products for Women's, Men's, and Kids.